Pompe Disease Treatment Market PPT: Overview, Dynamics, Trends, Segmentation, Application and Forecast to 2032

1
Global Pompe Disease Treatment Market Research
and Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Pompe Disease Treatment Market Global
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2024-2032," the global Pompe disease
  treatment market size reached US 1.0 Billion in
  2023.
• Factors Affecting the Growth of the Pompe Disease
  Treatment Industry
• Government and Regulatory Support
• Strong support from government bodies and
  regulatory agencies globally accelerates the
  growth of the pompe disease treatment industry.
  These entities often expedite the approval
  processes for new therapies and provide funding
  for research and development.
• Additionally, many countries have implemented
  newborn screening programs that include testing
  for Pompe disease, leading to early treatment
  initiation which can significantly improve
  patient outcomes. Moreover, such policies
  encourage pharmaceutical companies to invest in
  and develop new treatments and ensure that these
  innovations reach the market more swiftly,
  benefiting patients sooner.

4
Report Highlight and Description

• Increased Awareness and Diagnosis
• Growing awareness of pompe disease among
  healthcare professionals and the public leads to
  earlier and more accurate diagnoses, directly
  influencing the demand for treatment solutions.
  Additionally, educational campaigns and improved
  diagnostic tools, such as genetic testing, are
  identifying more individuals who can benefit from
  treatment early in their disease progression.
• As awareness increases, so does the engagement of
  medical communities and governments in addressing
  the needs of this patient population, thus
  further expanding the growth of the market for
  pompe disease treatments.
• Technological Advancements
• The growth of the Pompe disease treatment
  industry is primarily influenced by breakthroughs
  in biotechnology and genetic engineering. These
  advancements have led to the development of more
  effective enzyme replacement therapies (ERTs),
  which are crucial for treating Pompe disease by
  supplementing the deficient enzyme in patients.

5
Report Highlight and Description

• Additionally, progress in gene therapy offers the
  potential for long-term solutions by addressing
  the genetic root causes of the disease. Moreover,
  this continuous evolution in treatment approaches
  enhances patient outcomes and drives industry
  expansion as new and improved therapies become
  available to a broader patient base.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/pompe-disease-treatment
  -market/requestsample

6
Report Description

• Global Pompe Disease Treatment Market Trends
• The global Pompe disease treatment market is
  witnessing significant growth, primarily driven
  by the increasing adoption of enzyme replacement
  therapies (ERTs), which remain the cornerstone of
  treatment. There is a growing emphasis on
  advancing gene therapy techniques, promising
  potentially curative benefits, and addressing the
  underlying genetic causes of Pompe disease.
• Collaborations between pharmaceutical companies
  and biotech firms are also intensifying, aimed at
  accelerating the development and distribution of
  innovative therapies. Additionally, the market
  significantly benefits from enhanced investment
  in clinical trials to expand the efficacy and
  application range of existing treatments,
  ensuring continual improvements in patient care
  and outcomes and thus propelling market growth.
• Looking forward, IMARC Group expects the market
  to reach US 1.3 Billion by 2032, exhibiting a
  growth rate (CAGR) of 2.58 during 2024-2032.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/pompe-disease-treatment
  -market

7
Report Segmentation

• Treatment Insights
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Chaperone-Advanced Replacement Therapy (CART)
• Others
• Route of Administration Insights
• Oral
• Intravenous
• Others
• Distribution Channel Insights
• Hospital and Clinics Pharmacies
• Retail Pharmacies
• Online Pharmacies

8
Report Segmentation

• Others
• Indication Type Insights
• Infantile-Onset Pompe Disease (IOPD)
• Classic Infantile Form
• Non-Classic Infantile Form
• Late-Onset Pompe Disease (LOPD)
• Others
• Regional Insights
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

9
Competitive Landscape with Key Players

• Amicus Therapeutics Inc.
• Audentes Therapeutics Inc. (Astellas US Holding
  Inc.)
• Oxyrane UK Limited
• Sanofi S.A.
• Spark Therapeutics Inc

10
Key Questions Answered in the Report
11
Key Questions Answered in the Report
12
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Pompe Disease
  Treatment Market    5.1    Market Overview   
  5.2    Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Treatment
• 6.1 Enzyme Replacement Therapy (ERT)
• 6.1.1 Market Trends
• 6.1.2 Market Forecast
• 6.2 Substrate Reduction Therapy (SRT)
• 6.2.1 Market Trends
• 6.2.2 Market Forecast
• 6.3 Chaperone-Advanced Replacement Therapy
  (CART)
• 6.3.1 Market Trends
• 6.3.2 Market Forecast       

13
Table of Contents

• 6.4 Others
• 6.4.1 Market Trends
• 6.4.2 Market Forecast
• 7 Market Breakup by Route of Administration
• 7.1 Oral
• 7.1.1 Market Trends
• 7.1.2 Market Forecast
• 7.2 Intravenous
• 7.2.1 Market Trends
• 7.2.2 Market Forecast
• 7.3 Others
• 7.3.1 Market Trends
• 7.3.2 Market Forecast
• 8 Market Breakup by Distribution Channel
• 8.1 Hospital Clinics Pharmacies
• 8.1.1 Market Trends
• 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
• 8.2.1 Market Trends

14
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

15
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com